Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jul;26(7):457-62.
doi: 10.1155/2012/213828.

A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics

Emma Allen-Vercoe  1 , Gregor Reid, Norman Viner, Gregory B Gloor, Susy Hota, Peter Kim, Christine Lee, Kieran O'Doherty, Stephen J Vanner, J Scott Weese, Elaine O Petrof
Affiliations
Review

A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics

Emma Allen-Vercoe et al. Can J Gastroenterol. 2012 Jul.

Abstract
in English, French

A working group from across Canada comprised of clinician and basic scientists, epidemiologists, ethicists, Health Canada regulatory authorities and representatives of major funding agencies (Canadian Institutes of Health Research and the Crohn's and Colitis Foundation of Canada) met to review the current experience with fecal microbial therapy and to identify the key areas of study required to move this field forward. The report highlights the promise of fecal microbial therapy and related synthetic stool therapy (together called 'microbial ecosystems therapeutics') for the treatment of Clostridium difficile colitis and, possibly, other disorders. It identifies pressing clinical issues that need to be addressed as well as social, ethical and regulatory barriers to the use of these important therapies.

Un groupe de travail pancanadien composé de chercheurs cliniciens et fondamentaux, d’épidémiologistes, d’éthiciens, d’organismes de réglementation de Santé Canada et de représentants de grands organismes subventionnaires (Instituts de recherche en santé du Canada et Fondation canadienne des maladies inflammatoires de l’intestin) s’est réuni pour analyser l’expérience à jour en matière de thérapie microbienne fécale et déterminer les principaux domaines d’étude nécessaires pour faire progresser ce secteur. L’analyse souligne le caractère prometteur de la thérapie microbienne fécale et de la coprothérapie synthétique connexe (désignés collectivement « thérapeutique des écosystèmes microbiens ») pour traiter la colite à Clostridium difficile et, peut-être, d’autres troubles. Elle établit des enjeux cliniques pressants qu’il faut aborder ainsi que les obstacles sociaux, éthiques et en matière de réglementation liés à l’utilisation de ces thérapies importantes.

PubMed Disclaimer

Figures

Figure 1)
Figure 1)
A Canadian Working Group report on fecal transplant therapy: Microbial ecosystems therapeutics
See this image and copyright information in PMC

References

    1. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S12–18. - PubMed
    1. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442–9. - PubMed
    1. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ. 2004;171:466–72. - PMC - PubMed
    1. Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis. 2009;48:568–76. - PubMed
    1. Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe. 2009;15:285–9. - PubMed

Publication types

Grants and funding

LinkOut - more resources